Ann: CEO letter and Operational Update, page-15

thanks Tony. Im not sure if im missing something, just trying to join the dots. I know we got cre into the kidney cells and i know our matrix shows quite a bit of in vitro and in vivo success already. The thing i dont clearly understand is last i heared our lead fpp was not particularly cell specific and current (or last priority at least) was to scan for more cell specific fpp. That led me to believe that indications like kidney or heart cell penetration were good but dont as yet indicate the fpp is specific, it just means it has proven to penetrate these cells well, amongst others. The issue still being if given by iv will penetrate pretty much everything it contacts before it gets to liver etc? Results so far at least in vitro are all on specific isolated cell types aren't they? Its all good progress but i would love to understand exactly where we are at and where we need to be at.

Ie is this all just interesting science if we can't give by iv and have systemic cell specific penetration, or is there also a use for fpp if it has to be isolated and deliberately applied to target cells?